Value of Vaccines

Vaccines have eradicated many life-threatening diseases and have provided an unprecedented contribution to global public health. In the first half of this decade, the global vaccine market has developed into an attractive and highly profitable market that has drawn the attention of most, if not all, major pharmaceutical companies. The global vaccine market is outperforming the more traditional pharmaceutical markets, and has experienced an annual growth rate of more than 14%, surpassing the 30 billion USD mark in 2012-13. This growth will increase even further with many new innovative vaccines with blockbuster potential likely to reach the market in the coming years. Important growth drivers are the increased public awareness of infectious disease threats, such as seasonal and pandemic influenza, growth in government vaccine financial support, and scientific and technological breakthroughs that improve the efficacy of vaccines, address more challenging diseases and ultimately open up the possibility to develop therapies that fulfill previously unmet medical needs.

30.09.14 Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum
more >

22.05.14 Mucosis receives financial support from the Dutch government for its SynGEM® program
more >

15.04.14 Mucosis announces a strategic partnership with Changchun BCHT Biotechnology of China and raises additional capital
more >

12.08.13 Mucosis announces publication of data demonstrating safety and protection by mucosally administered Mimopath®-based prefusion-like F RSV vaccines
more >

16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >

08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >